Single nucleotide variants and predicted epitopes of tumor lines as deduced from transcriptome sequencing and bioinformatic analyses
| Mouse strain | BALB/c | |
| Tumor type | Meth A | CMS5 |
| RNA-Seq reads (million) | 105.8 | 23.4 |
| Genome mapped | 75% | 54% |
| Transcriptome mapped | 83% | 59% |
| HardMerge mapped | 65% | 48% |
| After PCR amplification filter | 18% | 22% |
| HardMerge and filtered mapped bases (Gb) | 1.15 | 0.24 |
| High-quality heterozygous SNVs in CCDS exonsa | 1,528 | 208 |
| Tumor specific | 1,504 | 191 |
| Non-synonymous | 77.1% | 78.5% |
| Missense | 1,096 | 146 |
| Nonsense | 63 | 4 |
| No-stop | 1 | - |
| NetMHC predicted epitopesb | 823 | 112 |
| H2 Kd-restricted | 203 | 15 |
| H2 Dd-restricted | 328 | 58 |
| H2 literd-restricted | 292 | 39 |
| Mouse strain | BALB/c | |
| Tumor type | Meth A | CMS5 |
| RNA-Seq reads (million) | 105.8 | 23.4 |
| Genome mapped | 75% | 54% |
| Transcriptome mapped | 83% | 59% |
| HardMerge mapped | 65% | 48% |
| After PCR amplification filter | 18% | 22% |
| HardMerge and filtered mapped bases (Gb) | 1.15 | 0.24 |
| High-quality heterozygous SNVs in CCDS exonsa | 1,528 | 208 |
| Tumor specific | 1,504 | 191 |
| Non-synonymous | 77.1% | 78.5% |
| Missense | 1,096 | 146 |
| Nonsense | 63 | 4 |
| No-stop | 1 | - |
| NetMHC predicted epitopesb | 823 | 112 |
| H2 Kd-restricted | 203 | 15 |
| H2 Dd-restricted | 328 | 58 |
| H2 literd-restricted | 292 | 39 |